Literature DB >> 1456181

Characterization and pharmacological modulation of soluble phospholipase A2 generated during glycogen-induced rat peritonitis.

L A Marshall1, J Murphy, L Marinari, J Chang.   

Abstract

Soluble phospholipase A2 (PLA2) activity was assessed in rat peritoneal lavage fluid after an intraperitoneal injection of 6% glycogen. Enzyme activity immediately increased 5-fold above basal by 4 h. Activity decreased by only 30% at 18 h and remained at this elevated level through 72 h. The initial rise in PLA2 activity was coincident with protein extravasation but not with polymorphonuclear leukocyte infiltration, suggesting that the early PLA2 activity could be, in part, blood-derived. Mononuclear cell influx occurred later (4 h), peaked by 6-8 h but remained elevated through 72 h possibly contributing to the persistence of PLA2 activity through 20-72 h. The exudate PLA2 measured at 4-6 h (early) and 20-24 h (late), after glycogen administration, were biochemically compared. They were found to be neutral pH active, Ca(2+)-dependent and were similarly inhibited by the inhibitors, p-bromophenacylbromide, ellagic acid, gossypol and luffariellolide. Oral administration of dexamethasone to rats inhibited the appearance of PLA2 activity in the peritoneal lavage fluid as well as cellular influx and protein extravasation. Indomethacin had no effect on these parameters. These studies demonstrate that PLA2 is an integral component of glycogen-induced peritonitis and can be pharmacologically manipulated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456181     DOI: 10.1007/bf01987891

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  29 in total

1.  Evaluation of antirheumatic drugs for their effect in vitro on purified human synovial fluid phospholipase A2.

Authors:  L A Marshall; J Bauer; M L Sung; J Y Chang
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

2.  Phospholipase activity in intact rat glycogen-elicited neutrophils.

Authors:  J Chang; E Blazek; A J Lewis
Journal:  Agents Actions       Date:  1986-01

3.  Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.

Authors:  W Pruzanski; E C Keystone; B Sternby; C Bombardier; K M Snow; P Vadas
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666

4.  Extracellular phospholipase A2 activity in cell free peritoneal lavage fluid from mice with zymosan peritonitis.

Authors:  K R Gans; S R Lundy; R L Dowling; T M Stevens; J S Kerr
Journal:  Agents Actions       Date:  1989-06

5.  Phospholipase A2-induced pleural inflammation in rats.

Authors:  B M Weichman; J W Berkenkopf; L A Marshall
Journal:  Int J Tissue React       Date:  1989

6.  The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2.

Authors:  P Vadas; W Pruzanski; J Kim; V Fornasier
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

7.  Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.

Authors:  P Vadas; J B Hay
Journal:  Can J Physiol Pharmacol       Date:  1983-06       Impact factor: 2.273

8.  Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation of the rabbit peritoneal cavity.

Authors:  M J Forrest; P J Jose; T J Williams
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

9.  Release of phospholipase A2 activity from rabbit peritoneal neutrophils by f-Met-Leu-Phe.

Authors:  C Lanni; E L Becker
Journal:  Am J Pathol       Date:  1983-10       Impact factor: 4.307

10.  Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.

Authors:  E Stefanski; W Pruzanski; B Sternby; P Vadas
Journal:  J Biochem       Date:  1986-11       Impact factor: 3.387

View more
  1 in total

1.  Prostaglandin E2 requirement for transforming growth factor beta 1 inhibition of elicited macrophage 14 kDa phospholipase A2 release.

Authors:  M McCord; B Bolognese; L A Marshall
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.